“Together, these changes will help ensure enrollees have consistent access to medically- necessary care while also maintaining medical management tools that emphasize the important role MA plans play in coordinating medically-necessary care,” CMS said.
Combination therapy with the novel agent BXCL701 and pembrolizumab showed strong clinical activity in in patients with platinum-resistant small cell neuroendocrine carcinoma metastatic castration-resistant prostate cancer.
The safety and efficacy of the Vivally System were established in the FREEOAB study, a prospective multi-center clinical trial that included 96 patients with overactive bladder.
Investigators found that the total out-of-pocket costs associated with oral therapies for prostate cancer were approximately 18 times higher compared with ADT.
The investigators identified several genetic factors, including ARID1A mutation, that correlated with survival outcomes in patients with advanced urothelial carcinoma treated with immune checkpoint blockade.
Clinical guidelines currently do not recommend PSMA-PET imaging before radical prostatectomy.
The Health Sector Cybersecurity Coordination Center of the US Department of Health and Human Services recently published a mobile device security checklist.
EHR measures are an indicator of how technology friendly your practice is.
“We recommend mirabegron monotherapy as an alternative medical treatment choice for the management of OAB,” the authors wrote.
"[This] could be a paradigm shift in prostate cancer,” says Eugene Shenderov, MD, PhD.
Study finds a 35% increase in vasectomy consultation requests.
Availability, expertise, and funding were the primary issues identified as barriers to use of sacral neuromodulation for the treatment of patients with overactive bladder.
In combination, the number of immune cells in and around kidney tumors, the amount of dead cancer tissue, and the mutations of PBRM1 can serve as biomarkers of response to immunotherapy in patients with kidney cancer.
The current study is welcome news as it lends further support to the use of intravesical Gem/Doce as a safe and effective option that has the potential to become a new standard of care for high-risk NMIBC.
The phase 2 LITESPARK-003 study explored belzutifan plus cabozantinib in patients with locally advanced or metastatic clear cell renal cell carcinoma.
Rebekah Bernard, MD, provides tips for improving interactions with patients who are angry.
The findings suggest creatinine-based eGFR equations alone may be inaccurate, and cystatin C or combined eGFR equations may be a more accurate assessment of kidney function in this population.
"When we put this course together, we didn't want it to be a course about working more; it was really about working more efficiently, so that you can gain more time outside of work," says Angela B. Smith, MD, MS.
At 5-year follow-up, overall survival among patients with kidney cancer who had quit smoking was 85% compared with 61% for those that continued to smoke.
Cleveland Clinic surgeons describe a new technique for harvesting a rectal mucosa graft.
Resist the temptation to overspend on unnecessary luxuries and upgrades.
Urologists weigh in on the challenges associated with whether, when, and how to treat these patients with prostate cancer.
"We are caring for a variety of patients who do not look like the physicians who are providing care to them," says Akanksha Mehta, MD, MS.
"We are confident that surgery for [testicular seminoma] will be included into treatment guidelines in the near future,” says Sia Daneshmand, MD.
Active surveillance is the preferred treatment option for men with low-risk prostate cancer and an option for some men with favorable intermediate-risk prostate cancer.
The approval of pembrolizumab plus enfortumab vedotin in urothelial cancer was supported by results from the EV-103/KEYNOTE-869 trial.
“These disparities are concerning as the generalizability of clinical trial results relies on the assumption that the population of patients included in a clinical trial represents the overall population of patients with the disease," says Brian M. Shinder, MD.
Apalutamide is approved by the FDA for the treatment of patients with non-metastatic castration-resistant prostate cancer or metastatic castration-sensitive prostate cancer.
Modifier -25 is defined as a significant, separately identifiable E/M service by the same physician or other qualified health care professional on the same day of the procedure or other service.
"In our sample, nearly 10% of patients [with prostate cancer] had a gene variant that made them eligible for effective new therapies, with faster results than traditional referral for genetic testing and counseling,” said Maria I. Carlo, MD.
